Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| GitLab | Lattice Semiconductor | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | narrow Lattice holds long-lived, low-power sockets that an outside analyst calls sticky, and it kept its gross profit high through a sharp revenue fall. But each new customer product is competed for again, and the 10-K concedes larger rivals. William Blair's research initiation (2026-10-06, https://www.williamblair.com/News/Lattice-Semiconductor-Corporation-Research-Initiation) says 'Lattice has built a leadership position in the high-volume, sticky sockets where power efficiency is critical'. The FY2025 10-K's financial data (as carried in TradingPilot fundamentals) report gross profit of $340,400 thousand on revenue of $509,401 thousand in fiscal 2024, when revenue fell from $737,154 thousand in fiscal 2023. Against that, the same 10-K says 'The selection process for our products to be included in our customers' new products is highly competitive' and 'There are no guarantees that our products will be included in the next generation'. It also says many competitors 'have substantially greater financial, technological, manufacturing, marketing, and sales resources than us'. Operating income was $11,232 thousand in fiscal 2025. Narrow rather than wide, because the sockets are re-won each product generation against larger competitors, and no independent share figure was found. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | switching costs The lock is the design socket and the product's long life. The FY2025 10-K cites 'a commitment to product longevity, with a large number of Lattice devices having been supported in the market for over 20 years'. It says the sales team works to 'drive multi-generational design wins', and that Lattice still supports FPGA families 'that have been in market for more than a decade and still garner strong customer demand today'. William Blair (2026-10-06) calls the same sockets 'sticky'. The 10-K limits the lock to products already designed in: selection for customers' new products 'is highly competitive'. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | co leader William Blair (2026-10-06) calls Lattice 'a leader in low-power programmable silicon' with 'a leadership position in the high-volume, sticky sockets where power efficiency is critical'. It gives no share figure, and it notes that 'larger FPGA competitors' focus on compute-intensive work. The 10-K's 'Lattice is the low power programmable leader' is the company's own claim. Without a tracker's share number, and with larger rivals in the wider FPGA market, the band is co-leader rather than clear leader. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | moderate Gross profit has stayed high through the cycle. The FY2025 10-K's financial data (as carried in TradingPilot fundamentals) show gross profit of $514,670 thousand on revenue of $737,154 thousand in fiscal 2023, $340,400 thousand on $509,401 thousand in fiscal 2024, and $356,943 thousand on $523,262 thousand in fiscal 2025. The 10-Q filed 2026-08-04 shows $141,332 thousand on $201,079 thousand for the quarter ended 2026-07-04. William Blair (2026-10-06) says Lattice is 'replacing legacy small footprint FPGAs with higher-price Nexus 2 devices'. The 10-K's risk factors still warn that downturns 'can result, and in the past has resulted, in ... erosion of average selling prices'. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | Lattice makes small and mid-range FPGAs that work as companion chips to a system's processors, or as primary processors, handling control, bridging, security and sensor connectivity in servers, communications gear, factories, cars and consumer devices. It competes on power and size rather than compute. William Blair says it 'specializes in low-power, small and midrange programmable silicon', while 'larger FPGA competitors focus on the compute-intensive market'. Distributors took approximately 84% of fiscal 2025 revenue, per the 10-K. In 2026 Lattice bought AMI for $1.65 billion, which William Blair says 'extends the company into platform firmware, security, and infrastructure manageability'. This profile rates the FPGA franchise described in the 10-K, not the newly acquired firmware business. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | Layer-4 companion silicon: low-power FPGAs for control, security and connectivity beside processors in servers and communications gear, and in industrial, automotive and consumer systems, mostly sold through distributors. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |